Correspondence 0001493152-24-005025 from Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532) (TELO)
Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532)
Date: Feb. 6, 2024 · CIK: 0001971532 · Accession: 0001493152-24-005025
AI Filing Summary & Sentiment
File numbers found in text: 333-275534
Letter
TELOMIR PHARMACEUTICALS, Inc.
900 West Platt Street, Suite 200
Tampa, Florida 33606
February 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549
Attn: Tara Harkins, Lynn Dicker, Jimmy McNamara, and Joe McCann
Re: Telomir Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed November 14, 2023
File No. 333-275534
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Telomir Pharmaceuticals, Inc., hereby requests that the above-referenced Registration Statement on Form S-1 be declared effective at 4:30 p.m., Eastern Standard Time, on Thursday, February 8, 2024, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Neda Sharifi and Curt Creely of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 359-8719 or (813) 225-4122.
Very truly yours,
TELOMIR pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
TELOMIR
PHARMACEUTICALS, Inc.
900 West Platt Street, Suite 200
Tampa, Florida 33606
February 6, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
D.C. 20549
Attn:
Tara Harkins, Lynn Dicker, Jimmy McNamara, and Joe McCann
Re:
Telomir
Pharmaceuticals, Inc.
Registration
Statement on Form S-1
Filed
November 14, 2023
File
No. 333-275534
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Telomir Pharmaceuticals, Inc., hereby requests
that the above-referenced Registration Statement on Form S-1 be declared effective at 4:30 p.m., Eastern Standard Time, on Thursday,
February 8, 2024, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Neda Sharifi and Curt
Creely of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 359-8719 or (813) 225-4122.
Very truly yours,
TELOMIR pharmaceuticals, Inc.
By:
/s/
Dr. Christopher Chapman, Jr.
Dr.
Christopher Chapman, Jr.
Chief
Executive Officer